Variables | Patients without Poor Outcome*, n = 47 | Patients with Poor Outcome*, n = 15 | p |
---|---|---|---|
Age > 35 yrs | 26 (55.3) | 9 (60) | 0.750 |
Male/female, n | 7/40 | 2/13 | 1.000 |
Delay in diagnosis, > 1 yr | 22 (46.8) | 9 (60) | 0.554 |
Elevated ESR at presentation† | 28 (59.6) | 9 (60) | 0.977 |
Elevated CRP at presentation‡ | 15 (31.9) | 2 (13.3) | 0.314 |
Renal insufficiency at presentation§ | 3 (6.4) | 5 (33.3) | 0.016 |
HTN at presentation | 30 (63.8) | 14 (93.3) | 0.047 |
Diabetes at presentation | 2 (4.3) | 1 (6.7) | 1.000 |
Dyslipidemia at presentation | 6 (12.8) | 3 (20.0) | 0.674 |
Limb claudication | 15 (31.9) | 7 (46.7) | 0.359 |
Decreased pulse | 35 (74.5) | 15 (100.0) | 0.029 |
Asymmetric blood pressure | 39 (83.0) | 13 (86.7) | 1.000 |
Vascular bruit | 14 (29.8) | 5 (33.3) | 1.000 |
Bilateral involvement | 23 (48.9) | 12 (80.0) | 0.041 |
Severity > 70% | 17 (36.2) | 9 (60.0) | 0.137 |
Antihypertensive drug | |||
Any | 30 (63.8) | 14 (93.3) | 0.047 |
ACE inhibitor or ARB | 10 (21.3) | 7 (46.7) | 0.094 |
B blocker | 9 (19.1) | 8 (53.3) | 0.018 |
Calcium-channel blocker | 24 (51.1) | 14 (93.3) | 0.005 |
Antiplatelet drug | |||
Any | 29 (61.7) | 9 (60.0) | 1.000 |
Aspirin | 22 (46.8) | 9 (60.0) | 0.554 |
Cholesterol-lowering drug | 26 (55.3) | 8 (53.3) | 1.000 |
Warfarin | 8 (17.0) | 4 (26.7) | 0.461 |
Corticosteroid | 31 (66.0) | 7 (46.7) | 0.363 |
Immunosuppressant | 30 (63.8) | 6 (40.0) | 0.228 |
Revascularization | 7 (14.9) | 4 (26.7) | 0.437 |
Significant data are in bold face.
↵* Poor outcome was defined as the composite of chronic renal insufficiency, refractory HTN, and/or death.
↵† Defined as ESR > 9 mm/h in men, > 20 mm/h in women.
↵‡ Defined as CRP > 0.6 mg/dl.
↵§ Defined as an estimated glomerular filtration rate < 60 ml/min. HTN: hypertension; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker.